Comparison of dynamic changes in the peripheral CD8+ T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy

Hui Wei, Yanqi Li, Zhoubo Guo, Xiaoxue Ma, Yang Li, Xiaoying Wei, Dong Han, Tian Zhang, Xi Chen, Cihui Yan, Jiahuan Zhou, Qingsong Pang, Ping Wang, Wencheng ZhangFrontiers in Immunology 2022 · DOI

TL;DR

This study investigated how two different cancer treatments—radiotherapy plus an anti-PD-1 antibody (camrelizumab) versus standard chemoradiotherapy (CCRT)—affect the immune system, specifically CD8+ T cells, in patients with esophageal cancer. While both treatments activated these crucial immune cells, the combination therapy showed a more significant impact on T cell differentiation and was associated with better patient outcomes, suggesting a more robust and potentially superior anti-tumor immune response.

What Problem Does This Paper Address?

Esophageal squamous cell carcinoma (ESCC) is a challenging cancer, often diagnosed at advanced stages. Concurrent chemoradiotherapy (CCRT) is a standard treatment, but its effectiveness can be limited. Immunotherapy, particularly using anti-PD-1 antibodies, has shown promise in various cancers. Combining radiotherapy with immunotherapy is a newer approach being explored to enhance treatment efficacy. However, a key question remains: how do these different treatment strategies dynamically alter the systemic immune landscape, particularly the function and differentiation of CD8+ T cells, which are critical for fighting cancer? Understanding these changes could shed light on why one treatment might be more effective than another and guide future therapeutic strategies.

Methods

The researchers conducted a prospective study comparing two groups of ESCC patients: one receiving radiotherapy combined with camrelizumab (an anti-PD-1 antibody) and another receiving standard CCRT. They collected peripheral blood samples before and during treatment. Using flow cytometry, they meticulously analyzed the expression of various markers on CD8+ T cells. These markers indicated:

  • Function: Eomes, T-bet, and IFN-γ (key proteins involved in T cell activity).
  • Activation: CD38 and HLA-DR (markers indicating T cells are actively responding).
  • Differentiation: CD45RA and CD62L (used to classify CD8+ T cells into subsets like naive, central memory (Tcm), effector memory (Tem), and terminally differentiated effector memory (TEMRA)).

They also specifically looked for camrelizumab binding to PD-1 on CD8+ T cells to confirm the drug's engagement. Statistical analyses were used to compare the expression levels and differentiation states between the two treatment groups and between PD-1-positive and PD-1-negative CD8+ T cells.

Datasets

The study utilized data from two patient cohorts:

  • Radiotherapy + Camrelizumab Group: 19 patients from a phase 1b clinical trial (NCT03222440).
  • CCRT Group: 18 patients treated concurrently.

No new public datasets were introduced or used for benchmarking.

Key Insights and Ideas

  • PD-1+ CD8+ T cells are inherently "primed" for action: Even before treatment, CD8+ T cells expressing PD-1 showed higher levels of functional and activation markers compared to their PD-1-negative counterparts. This suggests that PD-1 expression on CD8+ T cells might identify a subset already primed for anti-tumor activity.
  • Both treatments activate CD8+ T cells, but differently: Both radiotherapy plus camrelizumab and CCRT increased the expression of activation markers (CD38 and HLA-DR) on CD8+ T cells. However, the combination therapy showed a more pronounced impact on the differentiation of these T cells, shifting them towards memory phenotypes.
  • Camrelizumab effectively engages its target: The study confirmed that the anti-PD-1 antibody camrelizumab successfully bound to PD-1 on CD8+ T cells during treatment, indicating the drug was active in the patients.
  • Combination therapy leads to better outcomes: Crucially, patients treated with radiotherapy plus camrelizumab demonstrated significantly better overall survival (OS) and progression-free survival (PFS) compared to those receiving CCRT. This clinical outcome aligns with the observed more robust immune modulation by the combination therapy.

Key Results

  • Activation: Both treatments significantly increased CD38 and HLA-DR expression on CD8+ T cells.
  • Camrelizumab Binding: Approximately 10.48% of CD8+ T cells showed binding of camrelizumab during treatment.
  • Differentiation:
    • Radiotherapy + Camrelizumab significantly reduced naive and TEMRA subsets while increasing Tcm and Tem subsets in both PD-1+ and PD-1- CD8+ T cells.
  • CCRT had a less pronounced effect, primarily increasing Tcm and reducing TEMRA subsets in PD-1- CD8+ T cells, with minimal changes in PD-1+ CD8+ T cells.
  • Survival: Median OS was 54.97 months for the RT+Camrelizumab group versus 29.62 months for the CCRT group. Median PFS was 54.97 months versus 8.52 months, respectively.

Limitations and Future Work

The authors acknowledge the primary limitation of this study is its small sample size (n=19 for the combination therapy group), stemming from its phase 1b trial design. This makes the findings preliminary and necessitates further validation in larger cohorts. They also note that the CCRT group was collected during a similar period, but not as a direct randomized control, which could introduce some bias.

Future work should focus on:

  • Larger studies: Replicating these findings in larger, randomized controlled trials to confirm the observed differences in immune responses and clinical outcomes.
  • Mechanism elucidation: Further investigating the specific molecular mechanisms by which radiotherapy combined with immunotherapy drives distinct CD8+ T cell differentiation and activation patterns compared to CCRT.
  • Biomarker discovery: Exploring whether the observed changes in CD8+ T cell subsets can serve as predictive biomarkers for treatment response and prognosis in ESCC patients.

Summary updated

Abstract

This study identified the dynamic changes of systematic immune status of patients undergoing treatment. The two treatments had similar activation effects on peripheral CD8<sup>+</sup> T cells with different PD-1 properties but had different effects on their differentiation status. These results provided potential clues to the reasons underlying the difference in prognosis of the two treatments.
BibTeX
@inproceedings{wei2022comparison,
  author = {Hui Wei and Yanqi Li and Zhoubo Guo and Xiaoxue Ma and Yang Li and Xiaoying Wei and Dong Han and Tian Zhang and Xi Chen and Cihui Yan and Jiahuan Zhou and Qingsong Pang and Ping Wang and Wencheng Zhang},
  title = {{Comparison of dynamic changes in the peripheral CD8+ T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.1060695},
}
Figure